Stanford Researchers cite BioPharm Laboratories High Purity Thrombin
February 10, 2022
More accolades for BioUtah member BioPharm Laboratories – another journal article from the Journal of Biological Chemistry cites the use of BioPharm’s High Purity Thrombin being used to cleave protein in their protein purification process. This time from researchers at Stanford University.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic trait that can cause hemolytic anemia. To date, over 150 non-synonymous mutations have been identified in G6PD, with pathogenic mutations clustering near the dimer and/or tetramer interface and the allosteric NADP+-binding site. BioPharm has identified a small molecule which activates G6PD variants by stabilizing the allosteric NADP+ and dimer complex, suggesting therapeutics that target these regions may improve structural defects.
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
